Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents

BMC Pediatrics

John M Pellock²  Vicky Whittemore¹  Christine O’Dell⁴  Maria Hardin⁶  Kari Luther Rosbeck¹  Patricia A Gibson⁵  James W Wheless³ 

[1] Tuberous Sclerosis Alliance, 801 Roeder Road, Suite 750, Silver Spring, MD, 20910, USA;Division of Child Neurology, Department of Neurology, Virginia Commonwealth University School of Medicine, 1001 East Marshall Street, 1st Floor, Richmond, VA, 23298, USA;Clinical Chief and Director of Pediatric Neurology, St. Jude Children’s Research Hospital, 777 Washington Avenue, P335, Memphis, TN, 38105, USA;The Comprehensive Epilepsy Management Center, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA;Epilepsy Information Service, Comprehensive Epilepsy Program, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC, 27157, USA;7 Carpenter Close, Ridgefield, CT, 06877, USA

关键词: Infants;    Seizures;    Community resources;    Continuum of care;    Treatment;    Infantile spasms;    Vigabatrin;    ACTH;    Encephalopathic epilepsy;    West syndrome;   

Others  :  1170722
DOI  :  10.1186/1471-2431-12-108

 received in 2011-07-07, accepted in 2012-07-25,  发布年份 2012

【 摘 要 】

Background

Infantile spasms (IS; West syndrome) is a severe form of encephalopathy that typically affects infants younger than 2 years old. Pediatricians, pediatric neurologists, and other pediatric health care providers are all potentially key early contacts for families who have an infant with IS. The objective of this article is to assist pediatric health care providers in the detection of the disease and in the counseling and guidance of families who have an infant with IS.

Methods

Treatment guidelines, consensus reports, and original research studies are reviewed to provide an update regarding the diagnosis and treatment of infants with IS. Web sites were searched for educational and supportive resource content relevant to providers and families of patients with IS.

Results

Early detection of IS and pediatrician referral to a pediatric neurologist for further evaluation and initiation of treatment may improve prognosis. Family education and the establishment of a multidisciplinary continuum of care are important components of care for the majority of patients with IS. The focus of the continuum of care varies across diagnosis, initiation of treatment, and short- and long-term needs. Several on-line educational and supportive resources for families and caregivers of patients with IS were identified.

Conclusions

Given the possibility of poor developmental outcomes in IS, including the emergence of other seizure disorders and cognitive and developmental problems, early recognition, referral, and treatment of IS are important for optimal patient outcomes. Dissemination of and access to educational and supportive resources for families and caregivers across the lifespan of the child with IS is an urgent need. Pediatric health care providers are well positioned to address these needs.

【 授权许可】

   
2012 Wheless et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]West WJ: On a peculiar form of infantile convulsions. Lancet 1841, 1:724-725.
• [2]Pellock JM, Hrachovy RA, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al.: Infantile spasms: a U.S. consensus report. Epilepsia 2010, 51:2175-2189.
• [3]Commission on Pediatric Epilepsy of the International League Against Epilepsy: Workshop on infantile spasms. Epilepsia 1992, 33:195.
• [4]Hrachovy RA, Frost JD: Severe encephalopathic epilepsy in infants: infantile spasms (West syndrome). In Pediatric Epilepsy: Diagnosis and Therapy. Edited by Pellock JM, Bourgeois BF, Dodson WE, Nordli DR Jr, Sankar R. Demos Medical Publishing, New York, NY; 2008:249-268.
• [5]Riikonen R: A long-term follow-up study of 214 children with the syndrome of infantile spasms. Neuropediatrics 1982, 13:14-23.
• [6]Riikonen R: Epidemiological data of West syndrome in Finland. Brain Dev 2001, 23:539-541.
• [7]Trevathan E, Murphy CC, Yeargin-Allsopp M: The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia 1999, 40:748-751.
• [8]Ludvigsson P, Olafsson E, Sigurthardottir S, Hauser WA: Epidemiologic features of infantile spasms in Iceland. Epilepsia 1994, 35:802-805.
• [9]Wong M, Trevathan E: Infantile spasms. Pediatr Neurol 2001, 24:89-98.
• [10]Lombroso CT: A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983, 24:135-158.
• [11]Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S: Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004, 45:255-262.
• [12]Darke K, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Lux AL, et al.: Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010, 95:382-386.
• [13]Primec ZR, Stare J, Neubauer D: The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. Epilepsia 2006, 47:2202-2205.
• [14]Eisermann MM, DeLaRaillere A, Dellatolas G, Tozzi E, Nabbout R, Dulac O, et al.: Infantile spasms in Down syndrome–effects of delayed anticonvulsive treatment. Epilepsy Res 2003, 55:21-27.
• [15]Sharma NL, Vishwanthan V: Outcome in West syndrome. Indian Pediatr 2008, 45:559-563.
• [16]Goh S, Kwiatkowski DJ, Dorer DJ, Thiele EA: Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 2005, 65:235-238.
• [17]Jellinger K: Neuropathological aspects of infantile spasms. Brain Dev 1987, 9:349-357.
• [18]Paciorkowski AR, Thio LL, Dobyns WB: Genetic and biologic classification of infantile spasms. Pediatr Neurol 2011, 45:355-367.
• [19]Webb DW, Fryer AE, Osborne JP: Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 1996, 38:146-155.
• [20]Saemundsen E, Ludvigsson P, Rafnsson V: Autism spectrum disorders in children with a history of infantile spasms: a population-based study. J Child Neurol 2007, 22:1102-1107.
• [21]Saemundsen E, Ludvigsson P, Rafnsson V: Risk of autism spectrum disorders after infantile spasms: a population-based study nested in a cohort with seizures in the first year of life. Epilepsia 2008, 49:1865-1870.
• [22]Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA: Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia 2009, 50:290-296.
• [23]Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P: Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 2010, 14:146-149.
• [24]Jeavons PM, Bower BD: Infantile spasms: a review of the literature and a study of 112 cases. William Heinemann Medical Books, London, England; 1964.
• [25]Baram TZ: Pathophysiology of massive infantile spasms: perspective on the putative role of the brain adrenal axis. Ann Neurol 1993, 33:231-236.
• [26]Stafstrom CE: Infantile spasms: a critical review of emerging animal models. Epilepsy Curr 2009, 9:75-81.
• [27]Baram TZ: Models for infantile spasms: an arduous journey to the Holy Grail. Ann Neurol 2007, 61:89-91.
• [28]Brunson KL, Eghbal-Ahmadi M, Baram TZ: How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev 2001, 23:533-538.
• [29]Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD: Vigabatrin: 2008 update. Epilepsia 2009, 50:163-173.
• [30]Shields WD: Medical versus surgical treatment: which treatment when. Int Rev Neurobiol 2002, 49:253-267.
• [31]Shields WD: West's syndrome. J Child Neurol 2002, 17(suppl 1):S76-S79.
• [32]Hrachovy RA, Frost JD: Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome). J Clin Neurophysiol 2003, 20:408-425.
• [33]O'Callaghan FJ, Lux AL, Darke K, Edwards SW, Hancock E, Johnson AL, et al.: The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011, 52:1359-1364.
• [34]Lux AL, Osborne JP: A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004, 45:1416-1428.
• [35]Watanabe K, Negoro T, Aso K, Matsumoto A: Reappraisal of interictal electroencephalograms in infantile spasms. Epilepsia 1993, 34:679-685.
• [36]Hrachovy RA, Frost JD, Kellaway P: Hypsarrhythmia: variations on the theme. Epilepsia 1984, 25:317-325.
• [37]Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al.: Practice parameter: medical treatment of infantile spasms. Report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004, 62:1668-1681.
• [38]Riikonen R: Infantile spasms: infectious disorders. Neuropediatrics 1993, 24:274-280.
• [39]Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ: High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996, 97:375-379.
• [40]Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al.: The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004, 364:1773-1778.
• [41]Partikian A, Mitchell WG: Major adverse events associated with treatment of infantile spasms. J Child Neurol 2007, 22:1360-1366.
• [42]Riikonen R, Donner M: ACTH therapy in infantile spasms: side effects. Arch Dis Child 1980, 55:664-672.
• [43]Eidlitz-Markus T, Kivity S, Goldberg-Stern H, Haimi-Cohen Y, Zeharia A: Effect of high-dose glucocorticosteroid treatment for infantile spasms on quantitative bone parameters later in life. J Child Neurol 2012, 27:74-79.
• [44]Carmant L: Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand Suppl 2011, 192:36-47.
• [45]Gaily E, Jonsson H, Lappi M: Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009, 50:206-216.
• [46]Sergott RC, Wheless JW, Smith MC, Westall CA, Kardon RH, Arnold A, et al.: Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro Ophthalmol 2010, 34:20-35.
• [47]Sergott RC, Westall CA: Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand 2011, 192:48-56.
• [48]Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O: Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997, 26:389-395.
• [49]Vigevano F, Cilio MR: Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997, 38:1270-1274.
• [50]Elterman RD, Shields WD, Mansfield KA, Nakagawa J: Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416-1421.
• [51]Appleton RE, Peters ACB, Mumford JP, Shaw DE: Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999, 40:1627-1633.
• [52]Kongelbeck SR: Discharge planning for the child with infantile spasms. J Neurosci Nurs 1990, 22:238-244.
• [53]Winterkorn EB, Pulsifer MB, Thiele EA: Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 2007, 68:62-64.
• [54]Glauser TA: Following catastrophic epilepsy patients from childhood to adulthood. Epilepsia 2004, 45(Suppl 5):23-26.